细胞分裂周期相关2（CDCA2）是细胞分裂周期相关蛋白（CDCA）家族的成员之一，对细胞有丝分裂和DNA修复的调节至关重要。我们在这项研究中对CDCA2进行了广泛检查，以确定其在各种癌症中的作用。本研究研究了CDCA2在全癌和不同的分子和免疫亚群中的差异表达。此外，还利用受试者工作特征曲线（ROC）和Kaplan-Meier（KM）曲线评估了CDCA2在全癌中的诊断和预后意义。还研究了CDCA2在低级别胶质瘤（LGG）的不同临床亚群中的预后价值，并构建了预后评估模型。最后，还对CDCA2的潜在作用机制进行了研究，包括生物学功能、ceRNA网络、m6A修饰和免疫浸润。CDCA2在各种癌症中差异表达。 CDCA2可以高度准确地诊断和预测肿瘤，并且CDCA2的表达水平与许多癌症的预后有关。此外，CDCA2在LGG不同亚群中的表达水平也与预后密切相关。丰富分析结果显示，CDCA2主要富集在细胞周期、有丝分裂和DNA复制中。随后，预测到hsa-miR-105-5p靶向CDCA2。此外，在LGG中还发现了4个可能抑制hsa-miR-105-5p/CDCA2轴的长链非编码RNA。同时，CDCA2的表达与m6A相关基因和LGG中免疫细胞浸润水平有关。CDCA2可以作为全癌，特别是LGG中诊断和预后的新生物标志物。对于在LGG中开发新的靶向治疗，它可能是一个潜在的分子靶点。然而，为了确定，我们需要进行额外的生物实验来支持我们从生物信息学预测得出的结果。版权所有：© 2023年李等人。本文为开放获取文章，遵循创作公共等许可证条款，该条款允许不受限制地使用、分发和复制，前提是原始作者和出处得到认可。

Cell division cycle associated 2 (CDCA2), a member of the cell division cycle associated proteins (CDCA) family, is crucial in the regulation of cell mitosis and DNA repair. CDCA2 was extensively examined in our work to determine its role in a wide range of cancers.CDCA2 differential expression was studied in pan-cancer and in diverse molecular and immunological subgroups in this research. Additionally, the diagnostic and prognostic significance of CDCA2 in pan-cancer was also evaluated using receiver operating characteristic (ROC) and Kaplan-Meier (KM) curves. Prognostic value of CDCA2 in distinct clinical subgroups of lower grade glioma (LGG) was also investigated and a nomogram was constructed. Lastly, potential mechanisms of action of CDCA2 were interrogated including biological functions, ceRNA networks, m6A modification and immune infiltration.CDCA2 is shown to be differentially expressed in a wide variety of cancers. Tumors are diagnosed and forecasted with a high degree of accuracy by CDCA2, and the quantity of expression CDCA2 is linked to the prognosis of many cancers. Additionally, the expression level of CDCA2 in various subgroups of LGG is also closely related to prognosis. The results of enrichment analyses reveal that CDCA2 is predominantly enriched in the cell cycle, mitosis, and DNA replication. Subsequently, hsa-miR-105-5p is predicted to target CDCA2. In addition, 4 lncRNAs were identified that may inhibit the hsa-miR-105-5p/CDCA2 axis in LGG. Meanwhile, CDCA2 expression is shown to be associated to m6A-related genes and levels of immune cell infiltration in LGG.CDCA2 can serve as a novel biomarker for the diagnosis and prognosis in pan-cancer, especially in LGG. For the development of novel targeted therapies in LGG, it may be a potential molecular target. However, to be sure, we'll need to do additional biological experiments to back up our results from bioinformatic predictions.Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.